50 results about "Clinical performance" patented technology

An apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses is disclosed. Ophthalmic lenses may include, for example, contacts, glasses or intraocular lenses (IOLs). The apparatus, system and method may include a design tool for designing a lens for implantation in an eye having a plurality of characteristics, a simulator for simulating performance of the lens in at least one modeled eye having the plurality of characteristics, at least one input for receiving clinical performance of the lens in the eye having the plurality of characteristics, a comparator for comparing outcomes of the clinical performance and the simulated performance, and an optimizer for optimizing a subsequent one of the outcome of the clinical performance responsive to modification of the lens in accordance with modification to the simulated performance.

An apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses is disclosed. Ophthalmic lenses may include, for example, contacts, glasses or intraocular lenses (IOLs). The apparatus, system and method may include a design tool for designing a lens for implantation in an eye having a plurality of characteristics, a simulator for simulating performance of the lens in at least one modeled eye having the plurality of characteristics, at least one input for receiving clinical performance of the lens in the eye having the plurality of characteristics, a comparator for comparing outcomes of the clinical performance and the simulated performance, and an optimizer for optimizing a subsequent one of the outcome of the clinical performance responsive to modification of the lens in accordance with modification to the simulated performance.

Multi-metric surgery simulator devices, systems, and methods, involving at least one sensor configured to collect surgical training performance data relevant to at least one surgical task, the at least one sensor configured to operate with a surgical navigation system comprising a processor, the processor configurable, by way of a set of executable instructions storable in relation to a non-transitory medium, to perform at least one of analyze collected data, transform the collected data, and provide feedback in relation thereto; and at least one surgery simulator apparatus operatively coupled with the at least one sensor, the at least one surgery simulator apparatus configured to operate with a tracking system, whereby collected data is obtainable and clinical performance in relation to the at least one surgical task is quantitatively evaluable and progressively improvable.

The invention discloses a photoacoustic imaging device free of limitation of ultrasonic transducer frequency bands and a detection method of the photoacoustic imaging device. The photoacoustic imaging device comprises a photoacoustic excitation assembly, a photoacoustic signal detection assembly, a photoacoustic signal collection / processing assembly and a sample platform, the photoacoustic excitation assembly, the photoacoustic signal detection assembly and the photoacoustic signal collection / processing assembly are sequentially connected, the photoacoustic excitation assembly and the photoacoustic signal collection / processing assembly are connected, and the photoacoustic signal detection assembly is connected with the sample platform. According to the photoacoustic imaging device, pulse lasers are used for radiating a biological sample to generate photoacoustic signals, continuous lasers with narrow line width are focused on the surface of the sample, vibration speeds of the surface of the sample are detected to achieve the purpose of detecting the photoacoustic signals, the defect of bandwidth limitation of the transducer is overcome, and the defects that high frequency photoacoustic signals are sharply attenuated in biological tissues and can not be detected are overcome; detection portions are not required to be subjected to any processing, requirements for imaging environment conditions are low, and large pushing functions on clinical performances of photoacoustic technology are achieved.

A method and system for providing performance evaluations, on a timely basis, to students or trainees, is provided. In one contemplated embodiment, the inventive method and system are used in health care training programs to form an information feedback loop whereby clinical and simulated clinical performance evaluations are inputted, or gathered and stored, and then made available to the health care practitioner and to his / her educator(s) throughout the health care training program thereby increasing the effectiveness of the training program by allowing the program to be continuously tailored to address the needs of the health care practitioner.

A method for calculating and reporting image quality properties of an image acquisition device after a subject or object has been scanned consists of a scan quality monitoring system with automated software for receiving scans and radiation dose data from scanners and automated algorithms for analyzing image quality metrics and radiation dose tradeoffs. Image quality assessment methods include algorithms for measuring fundamental imaging characteristics, level and type of image artifacts, and comparisons against large databases of historical data for the scanner and protocols. Image quality reports are further customized to report on expected clinical performance of image detection or measurement tasks.

The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

Tumor Necrosis Factor-α (TNFα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of TNF production is implicated in a variety of human diseases including Alzheimer's disease, cancer, major depression, and inflammatory bowel disease. These disorders are treated with a TNFα inhibitor. Embodiments herein provide methods of preventing and / or treating acute and chronic inflammation, and autoimmune diseases by administering a prophylactic and / or therapeutic formulation containing an antibody fragment (Fab or F(ab′)2) of adalimumab modified by conjugation of natural amino acids such as proline, alanine and / or serine (PA / S) by PASylation®, and / or unnatural amino acids such as cysteine and other derivatives, thereby creating a polypeptide possessing none of the processing, preparation, formulation, cost, clinical performance, and other long-term issues of administering PEGylated drugs.

Embodiments of clinical support systems and methods are disclosed. In one embodiment, methods for clinical performance measurement are disclosed comprising defining a range of acceptable treatment variable values for a treatment variable of a subject, performing a selected intervention, determining an affected treatment variable value and determining a selection performance measure by comparing the affected treatment variable value to the acceptable treatment variable values. In one embodiment, methods for clinical decision training are disclosed comprising defining a treatment variable of a simulated subject, selecting an intervention on the treatment variable, modeling the selected intervention and presenting a visual representation of the selected intervention. In one embodiment, methods for clinical decision support are disclosed comprising defining a treatment variable of a subject, presenting a decision support variable as clinical decision support, performing a selected intervention and determining an affected treatment variable value.

Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.

Provided herein are compositions, comprising hyaluronic acid in three different forms. The compositions are in a form of an essentially homogeneous gel with improved rheological properties enabling improved clinical performance.

The invention belongs to the technical field of bioscience, and particularly relates to a primates Parkinson's disease (PD) model behavior assessment optimal method. The method comprises the steps of establishing a rhesus monkey PD animal model; injecting MPTP into muscle of a rhesus monkey once a day till typical and stable PD clinical symptoms appear, wherein dosage is 0.2-0.5 mg / kg according to individual sensitivity difference; conducting behavior assessment on the rhesus monkey at two fixed time periods each day while MPTP injection is conducted, and taking the average score of one week as the final score of the week. A set of complete primates PD model behavior assessment method is provided and can be used for new drug efficacy assessment and horizontal and vertical comparative study of different new drugs. The assessment method absorbs the advantages and discards the disadvantages of different rating scales, and can reflect individual clinical difference comprehensively and accurately based on practical experience and clinical performance characteristics of rhesus monkeys, and individual clinical difference includes individual sensitivity difference, disease severity difference, disease sequence difference and individual PD feature difference.

The present invention relates to a web-based platform to track medical clinical assignments and to link embedded evaluation instruments to procedure type, for the optimization and improvement of medical clinical education and performance for healthcare professions, and in particular for graduate residents, such as surgical residents. This model is the basis for the platform for physician scoring and profiling to determine physician educational and performance competency with a selected medical procedure. The invention provides methods and systems for improving or optimizing performance tracking of a medical professional.

The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.